Overexpression of ANLN contributed to poor prognosis of anthracycline-based chemotherapy in breast cancer patients-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Overexpression of ANLN contributed to poor prognosis of anthracycline-based chemotherapy in breast cancer patients

Published:2017-02-27 Issue:3 Volume:79 Page:535-543
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Wang Zhan,Chen Juan,Zhong Mei-Zuo,Huang Juan,Hu Yuan-Ping,Feng De-Yun,Zhou Zhi-Jiao,Luo Xiao,Liu Zhao-Qian,Jiang Wu-Zhong,Zhou Wei-Bing

Funder

National Natural Science Foundation of China

Fundamental Research Funds for the Central Universities of Central South University

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-017-3248-2.pdf

Reference42 articles.

1. Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA Cancer J Clin 65(1):5–29. doi: 10.3322/caac.21254

2. Fan L, Strasser-Weippl K, Li JJ, St Louis J, Finkelstein DM, Yu KD, Chen WQ, Shao ZM, Goss PE (2014) Breast cancer in China. Lancet Oncol 15(7):e279–e289. doi: 10.1016/S1470-2045(13)70567-9

3. Winchester DP (2011) Post-treatment surveillance of breast cancer patients in an organized, multidisciplinary setting. J Surg Oncol 103(4):358–361. doi: 10.1002/jso.21713

4. von Minckwitz G, Raab G, Caputo A, Schutte M, Hilfrich J, Blohmer JU, Gerber B, Costa SD, Merkle E, Eidtmann H, Lampe D, Jackisch C, du Bois A, Kaufmann M (2005) Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol 23(12):2676–2685. doi: 10.1200/JCO.2005.05.078

5. Mamounas EP, Bryant J, Lembersky B, Fehrenbacher L, Sedlacek SM, Fisher B, Wickerham DL, Yothers G, Soran A, Wolmark N (2005) Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol 23(16):3686–3696. doi: 10.1200/JCO.2005.10.517

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Circular RNAs as a novel molecular mechanism in diagnosis, prognosis, therapeutic target, and inhibiting chemoresistance in breast cancer;Pathology - Research and Practice;2024-11

2. PP2A-B56 regulates Mid1 protein levels for proper cytokinesis in fission yeast;2024-06-29

3. Anillin contributes to prostate cancer progression through the regulation of IGF2BP1 to promote c-Myc and MAPK signaling;American Journal of Cancer Research;2024

4. Anillin(ANLN) promoting melanoma malignant progression via miR-200b-3p/ANLN/CDK1/p53 signaling axis;2023-06-01

5. N⁶-Methyladenosine Modification of ANLN Enhances Hepatocellular Carcinoma Bone Metastasis;International Journal of Biological Sciences;2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3